- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 952 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 18.12.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ImageneBio: Wedbush startet Coverage mit negativem Votum und Kursziel 2 US-Dollar | 2 | Investing.com Deutsch | ||
| 25.11.25 | Wedbush assumes coverage of ImageneBio stock with Underperform rating | 2 | Investing.com | ||
| 19.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 12.11.25 | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 457 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12.11.25 | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.25 | ImageneBio ernennt CEO Kristin Yarema zur Interims-Finanzchefin | 2 | Investing.com Deutsch | ||
| 22.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.08.25 | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 197 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 25.07.25 | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 323 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 23.07.25 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 308 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 15.07.25 | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 305 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen | |
| 11.07.25 | Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals | 180 | GlobeNewswire (Europe) | BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," the "Company") today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,270 | -3,55 % | Evotec-Aktie: Dieser Tag entscheidet | Die Evotec-Aktie hat heute einen wichtigen Tag vor sich. Der Aktienkurs muss unbedingt die Kursmarke bei 5,40 Euro verteidigen, ansonsten wird ein neues Kursziel aktiviert werden, das dann sinkende... ► Artikel lesen | |
| BIOGEN | 160,15 | +0,57 % | Biogen Inc.: The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome | -Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease-
-Data support... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,575 | +0,51 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| MAINZ BIOMED | 0,833 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt 6,0 Millionen USD Privatplatzierung und strategisches Update bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt 6,0 Millionen USD Privatplatzierung und strategisches Update bekannt
17.02.2026 /... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 93,40 | -0,43 % | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| GALAPAGOS NV | 28,060 | -0,64 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; March 6, 2026, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,670 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,686 | +3,82 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| CYTOKINETICS | 52,50 | +0,96 % | Cytokinetics auf Leerink-Konferenz: Strategischer Wachstumskurs in der Kardiologie | ||
| COHERUS ONCOLOGY | 1,638 | +4,73 % | Coherus BioSciences Q4 2025 Earnings Preview | ||
| SENSEI BIOTHERAPEUTICS | 28,800 | 0,00 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,998 | -1,19 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 | ||
| BIOAGE LABS | 16,900 | -3,43 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen |
IMAGENEBIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.